Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Dynavax Technologies Corporation (DVAX - Snapshot Report) reported a loss of 9 cents per share in the second quarter of 2013, a penny narrower than the Zacks Consensus Estimate of a loss of 10 cents per share, but flat year over year.

Dynavax reported revenues of $3.4 million, up 26.4% from the year-ago period and above the Zacks Consensus Estimate of $3 million.

Collaboration revenues came in at $1.4 million, down 16.4% from the year-ago quarter.

Grant revenue from Dynavax’ contract for adjuvant development awarded by the National Institutes of Health grew 58.1% to $1.4 million from the year-ago quarter.

Research and development expenses came in at $12.8 million in the second quarter of 2013, up 12.5% driven primarily by the purchase of components for hepatitis B vaccine candidate, Heplisav.

General and administrative expenses surged 28.1% to $7.6 million. Incremental severance expenses contributed to the increase.

We remind investors that Dynavax is developing Heplisav, in collaboration with GlaxoSmithKline (GSK - Analyst Report). Heplisav is currently under review in the US and Europe.

However, Dynavax received a setback in its efforts to get the candidate approved in the U.S. in Jun 2013 when the U.S. Food and Drug Administration (FDA) asked for additional safety data to approve its Biologic License Application (BLA).

Dynavax had conducted a meeting with the agency in Jun 2013 to discuss the Complete Response Letter (CRL) issued by the latter in Feb 2013 refusing to approve Heplisav in patients in the age group of 18-70 without further evaluation of safety.

Dynavax currently does not have any approved product in its portfolio. We expect investor focus to remain on Heplisav updates in the near term.

Apart from Heplisav, Dynavax is also developing AZD1419, for the treatment of asthma, in partnership with AstraZeneca (AZN - Analyst Report).

Dynavax carries a Zacks Rank #2 (Buy). Right now, Anika Therapeutics Inc. looks more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%